Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Use of HDAC Inhibitors for the Prevention and Cure for Brain Metastases of Cancers

Posted Jun 15 2010 5:00pm

Description of Invention:
The increased survival of primary and metastatic cancers consequential of improved therapies has resulted in increased brain metastases. Few treatment options are available for cancer patients with central nervous system (CNS) metastasis. There is a need for new treatment options for CNS metastases especially brain metastases originating outside the CNS.

The present invention provides a method of treating a localized carcinoma CNS metastasis of extra-CNS origin. More specifically, the method comprises of treating a localized carcinoma CNS metastasis of extra-CNS origin with a histone deacetylase (HDAC) inhibitor (HDACI) originating in one or more organs such as lung, breast, liver, colon, and prostate. The HDACI can be any HDACI that is capable of crossing the blood-brain barrier (BBB) such as vorinostat.

Advantages:
Vorinostat has been approved by the FDA for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies, and as such, has efficacy and tolerability data.

Development Status:
In vivo animal model data available with vorinostat.

Inventors:
Patricia S Steeg (NCI)


Patent Status:
HHS, Reference No. E-084-2007/0
US, Application No. 12/528,597 filed 25 Aug 2009



Portfolios:
Cancer
Cancer - Therapeutics
In-vivo Data



For Additional Information Please Contact:
Samuel Bish Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: bishse@mail.nih.gov
Phone: 301-435-5282
Fax: 301-402-0220


Ref No: 1677

Updated: 06/2010

Post a comment
Write a comment:

Related Searches